CT findings in patients with gliomas, surviving more than 10 years

Hatanaka, Hisashi; Sano, Kyouhei; Kitamura, K; Fukui, Miho; Mogami, Heitaro; Ushio, Yukitaka; Kuwabara, Takeo; Kyuma, Yoshikazu; Inaba, Y; Hatta, Hideo; Suzuki, Jirô; Katakura, Ryuichi; Takakura, K; Handa, H; Yasmashita, J.

doi:10.1055/s-2008-1053669

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a few patients (about 3%) live more than 5 years [1,4,7,[8][9][10][11][12][13]. Given the relatively few patients who are thought to have survived more than 5 years and the generally nihilistic attitude towards the subject as a whole, it is understandable that no large series of long-term survivors has been studied [11, [14][15][16][17][18][19][20][21][22]. We report the case of a long-term survivor and discuss the treatment and prognosis of glioblastoma.…”

Section: Introductionmentioning

confidence: 99%

Long-term survival in a patient with supratentorial glioblastoma: clinical considerations

1998

View full text Add to dashboard Cite

Glioblastoma, a malignant tumor of neuroepithelial origin, is relatively uncommon in childhood, during which it accounts for 7%-9% of brain tumors. A few patients (about 3%) live more than 5 years. We report a 13-year-old girl who was admitted because one month earlier she had begun to present headache and diplopia. Brain computed tomography (CT) showed a right frontal tumor. At operation, complete excision of the visible tumor was performed. Histologic examination showed that the tumor was a glioblastoma multiforme. The patient underwent 52 Gy of external beam radiotherapy to the enhancing tumor mass plus 3-cm border, and chemotherapy with nitrosourea (BCNU). Fourteen years, 9 months later, the patient presents neither neurological deficits nor radiological relapse. We confirm that younger age, the one immutable prognostic factor, supports a particularly aggressive approach to the treatment of glioblastomas.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-term survival in a patient with supratentorial glioblastoma: clinical considerations

1998

View full text Add to dashboard Cite

show abstract

Long-term survival with glioblastoma multiforme

Krex

Klink

Hartmann

et al. 2007

Brain

778

599

View full text Add to dashboard Cite

The median survival of glioblastoma patients is approximately 12 months. However, 3-5% of the patients survives for more than 3 years and are referred to as long-term survivors. The clinical and molecular factors that contribute to long-term survival are still unknown. To identify specific parameters that might be associated with this phenomenon, we performed a detailed clinical and molecular analysis of 55 primary glioblastoma long-term survivors recruited at the six clinical centres of the German Glioma Network and one associated centre. An evaluation form was developed and used to document demographic, clinical and treatment-associated parameters. In addition, environmental risk factors, associated diseases and occupational risks were assessed. These patients were characterized by young age at diagnosis and a good initial Karnofsky performance score (KPS). None of the evaluated socioeconomic, environmental and occupational factors were associated with long-term survival. Molecular analyses revealed MGMT hypermethylation in 28 of 36 tumours (74%) investigated. TP53 mutations were found in 9 of 31 tumours (29%) and EGFR amplification in 10 of 38 tumours (26%). Only 2 of 32 tumours (6%) carried combined 1p and 19q deletions. Comparison of these data with results from an independent series of 141 consecutive unselected glioblastoma patients registered in the German Glioma Network revealed significantly more frequent MGMT hypermethylation in the long-term survivor group. Taken together, our findings underline the association of glioblastoma long-term survival with prognostically favourable clinical factors, in particular young age and good initial performance score, as well as MGMT promoter hypermethylation.

show abstract

Autopsy Findings in a Long-term Survivor With Glioblastoma Multiforme —Case Report—

Yamada

Endo

Hirose

et al. 1998

Neurol. Med. Chir.(Tokyo)

View full text Add to dashboard Cite

Autopsy detected no tumor tissues in a patient who died 6.5 years after the diagnosis of glioblastoma multiforme. A 54-year-old male developed left hemiparesis one month prior to admission. Computed tomography demonstrated a cystic lesion in the right frontal region with irregular ring-like enhance ment. The tumor was extensively removed together with the surrounding tissues followed by irradia tion (whole brain 32.4 Gy, local 28.8 Gy), and intravenous administration of interferon-β. Histological examination confirmed the diagnosis of glioblastoma multiforme. He died of accidental head trauma 6.5 years after surgery. Autopsy of the brain detected no evidence of glioblastoma multiforme. The only findings were cerebral edema and hematoma caused by head trauma, as well as histological changes due to radiation damage. This case apparently confirms the histological disappearance of tumor tissue in a long-term survivor with glioblastoma multiforme.

show abstract

CT findings in patients with gliomas, surviving more than 10 years

Cited by 3 publications

References 0 publications

Long-term survival in a patient with supratentorial glioblastoma: clinical considerations

Long-term survival in a patient with supratentorial glioblastoma: clinical considerations

Long-term survival with glioblastoma multiforme

Autopsy Findings in a Long-term Survivor With Glioblastoma Multiforme —Case Report—

Contact Info

Product

Resources

About